Downregulation of Key Early Events in the Mobilization of Antigen-bearing Dendritic Cells by Leukocyte Immunoglobulin-like Receptor B4 in a Mouse Model of Allergic Pulmonary Inflammation by Fanning, Laura B. et al.
 
Downregulation of Key Early Events in the Mobilization of Antigen-
bearing Dendritic Cells by Leukocyte Immunoglobulin-like Receptor
B4 in a Mouse Model of Allergic Pulmonary Inflammation
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Fanning, Laura B., Carolyn C. Buckley, Wei Xing, Rebecca G.
Breslow, and Howard R. Katz. 2013. Downregulation of key early
events in the mobilization of antigen-bearing dendritic cells by
leukocyte immunoglobulin-like receptor b4 in a mouse model of
allergic pulmonary inflammation. PLoS ONE 8(2): e57007.
Published Version doi:10.1371/journal.pone.0057007
Accessed February 19, 2015 11:59:07 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10589785
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAADownregulation of Key Early Events in the Mobilization
of Antigen-bearing Dendritic Cells by Leukocyte
Immunoglobulin-like Receptor B4 in a Mouse Model of
Allergic Pulmonary Inflammation
Laura B. Fanning, Carolyn C. Buckley, Wei Xing, Rebecca G. Breslow, Howard R. Katz*
From the Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America, and the Division of Rheumatology, Immunology and Allergy,
Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
Abstract
Leukocyte Immunoglobulin-like Receptor B4 (LILRB4) null mice have an exacerbated T helper cell type 2 (Th2) immune
response and pulmonary inflammation compared with Lilrb4
+/+ animals when sensitized intranasally with ovalbumin (OVA)
and low-dose lipopolysaccharide (LPS) followed by challenge with OVA. Moreover, OVA-challenged Lilrb4
2/2 mice exhibit
greater migration of antigen (Ag)-bearing dendritic cells (DCs) to lymph nodes and accumulation of interleukin 4- and
interleukin 5-producing lymph node lymphocytes. The main objective of this study was to determine how the absence of
LILRB4 leads to a greater number of DCs in the lymph nodes of Ag-challenged mice and increased lung Th2 inflammation.
Mice were sensitized intranasally with PBS alone or containing OVA and LPS; additional cohorts were subsequently
challenged with OVA. Expression of chemokine (C-C motif) ligand 21 (CCL21) in the lung was assessed immunohistolog-
ically. OVA ingestion and expression of LILRB4 and chemokine (C-C motif) receptor 7 (CCR7) were quantified by flow
cytometry. Inhalation of OVA and LPS induced upregulation of LILRB4 selectively on lung Ag-bearing DCs. After sensitization
and challenge, the lung lymphatic vessels of Lilrb4
2/2 mice expressed more CCL21, a chemokine that directs the migration
of DCs from peripheral tissue to draining lymph nodes, compared with Lilrb4
+/+ mice. In addition, lung DCs of challenged
Lilrb4
2/2 mice expressed more CCR7, the CCL21 receptor. The lungs of challenged Lilrb4
2/2 mice also contained
significantly greater numbers of CD4+ cells expressing interleukin-4 or interleukin-5, consistent with the greater number of
Ag-bearing DCs and Th2 cells in lymph nodes and the attendant exacerbated Th2 lung pathology. Our data establish a new
mechanism by which LILRB4 can downregulate the development of pathologic allergic inflammation: reduced upregulation
of key molecules needed for DC migration leading to decreases in Th2 cells in lymph nodes and their target tissue.
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Introduction
Dendritic cells (DCs) are among the earliest participants in the
initiation of both protective and pathologic adaptive immunity and
inflammation. In response to danger signals such as lipopolysac-
charide (LPS), immature tissue DCs undergo an innate immune
maturation process so as to degrade endocytosed antigen (Ag) and
present peptides in association with highly expressed cell surface
major histocompatibility molecules in concert with upregulated
costimulatory molecules. This leads to expansion of Ag-specific
effector T cells in tissue-draining lymph nodes (LNs), a hallmark of
adaptive immunity [1]. An essential step in this process is the
migration of tissue DCs to draining LNs, where Ag-bearing
mature DCs attract and activate cognate Ag-specific T cells,
leading to their proliferation, polarization, and migration from the
LNs to the blood [2–4]. This process occurs not only in the
initiation of immune responses, but also at the beginning of
inflammatory responses that can occur upon re-exposure to Ag.
For example, challenge of Ag-sensitized animals by Ag inhalation
results in increased numbers of airway DCs and migration of the
cells to the lung-draining LNs, particularly in the first 24 hours
after challenge [5–8]. Similarly, there is a rapid increase in the
number of DCs in the bronchial mucosa of individuals with
allergic asthma in response to inhaled allergen challenge [9]. Lung
DCs that respond to Ag challenge in sensitized animals play a
significant role in increasing the number of pulmonary T cells and
their ability to generate T helper cell type 2 (Th2) cytokines in
response to Ag, as well as in the development of eosinophilic
airway inflammation, goblet cell hyperplasia, and airway hyper-
responsiveness [10–12]. Whereas much is known about the innate
immune signals that initiate this process through the migration of
Ag-bearing DCs to LNs, less is understood about control
mechanisms that inhibit DC migration and the subsequent
development of pathologic adaptive immune inflammation.
We have shown that the cell surface receptor Leukocyte
Immunoglobulin-like Receptor B4 (LILRB4) is a potent inhibitory
regulator of LPS-induced, neutrophil-dependent inflammation
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e57007[13–15]. More recently, we discovered a regulatory role for
LILRB4 on DCs [16] in a mouse model of Th2 pulmonary
inflammation induced by inhalation sensitization with OVA and a
low dose of LPS followed by inhalation challenge with ovalbumin
(OVA) two weeks later [17]. Low doses of inhaled LPS also
exacerbate pathologic Th2 airway responses in humans and
augment influx of myeloid DCs into the airways of patients with
allergic asthma [18,19]. In our model, Lilrb4
2/2 mice have
exacerbated Th2 pathology consisting of greater amounts of
eosinophilia and epithelial goblet cell metaplasia in the lung,
OVA-specific serum IgE, and production of Th2 cytokines by
OVA-restimulated lung-draining LN cells [16]. We also found that
expression of LILRB4 is selectively upregulated on OVA
+ DCs in
the LNs during sensitization of Lilrb4
+/+ mice. Moreover, the LNs
of OVA-challenged Lilrb4
2/2 mice have a significantly greater
number of OVA
+ mature DCs that contain a greater amount of
Ag, as well as more interleukin (IL) 4- and IL-5-producing
lymphocytes, compared with Lilrb4
+/+ mice [16]. Upregulation of
Ag uptake by airway DCs is associated with the progression of
allergic airway inflammation [20]. The greater Th2 pathology of
Lilrb4
2/2 mice is reiterated in Lilrb4
+/+ mice sensitized by
inhalation of Lilrb4
2/2 DCs previously pulsed with OVA/LPS
in vitro and challenged two weeks later by inhalation of OVA,
compared with mice sensitized with Lilrb4
+/+ DCs, which indicates
that LILRB4 expressed on DCs is sufficient to downregulate the
detrimental allergic airway responses [16]. The mechanism by
which LILRB4 decreases the number of Ag-bearing lung DCs that
appear in the draining LNs after Ag challenge represents a
fundamental control step in the development of allergic pulmo-
nary inflammation. Hence, we sought to determine how LILRB4
regulates this aspect of DC pathobiology.
Chemokine (C-C motif) ligand 21 (CCL21) is a chemoattractant
for DCs in vitro and plays a key role in regulating the migration of
tissue DCs to draining LNs [21–27]. Upregulation of CCL21 on
lymphatic endothelium can be a rate-limiting step in DC
migration from peripheral tissue to draining LNs [28]. In the
lung, CCL21 is located in perivascular lymphatic vessels [23]. A
large body of evidence indicates that expression of chemokine (C-
C motif) receptor 7 (CCR7; the receptor for CCL21) on DCs is
essential for their entry into lymphatic vessels [22,24,27,29–31],
including lung DCs carrying inhaled OVA [32]. Upregulation of
CCR7 expression on DCs accompanies maturation induced by
LPS, tumor necrosis factor a (TNF-a), and other proinflammatory
mediators [33–36]. We therefore hypothesized that the greater
number of OVA
+ DCs in the LNs of OVA-challenged Lilrb4
2/2
mice was the result of enhanced migration of the cells from the
lung to LNs. We now report that LILRB4 is selectively
upregulated on OVA
+ DCs in the lungs of OVA/LPS-sensitized
Lilrb4
+/+ mice when challenged with OVA, indicating that this
effect, previously observed in the draining LNs [16], occurs first in
the lung. We also show that expression of CCL21 on lung
lymphatic vessels and CCR7 on OVA
+ lung DCs is increased after
challenge of OVA/LPS-sensitized Lilrb4
+/+ and Lilrb4
2/2 mice,
but the increases are significantly greater in the Lilrb4
2/2 strain.
In accordance with the greater number of OVA
+ DCs and Th2
cells in the LNs of Lilrb4
2/2 mice [16], the number of Th2 cells in
the lungs of Ag-challenged Lilrb4
2/2 mice is significantly greater
than that of Lilrb4
+/+ animals. Our data reveal that LILRB4
downregulates the expression of two key molecules that induce the
migration of Ag-bearing lung DCs to LNs, thereby attenuating
Th2 cell accumulation in LNs and lung as well as ensuing
pathologic inflammation.
Methods
Animals
Lilrb4
+/+ and Lilrb4
2/2 mice were generated on the BALB/c
background as previously described [14]. Mice were maintained in
a specific pathogen-free barrier facility. Female mice, 6–12 weeks
old, were used for experiments. Mice were anesthetized for all
intranasal instillations to minimize discomfort. The use of mice for
these studies was reviewed and approved by the Animal Care and
Use Committee of the Dana-Farber Cancer Institute (Protocol
#03-139), and complied with the U.S. Public Health Service
Policy on Humane Care and Use of Laboratory Animals, 2002.
Sensitization and challenge protocol
Mice were lightly anesthetized with isoflurane and then
sensitized intranasally with 50 ml of PBS alone or containing
100 mg of OVA (Grade V, Sigma-Aldrich, St. Louis, MO) and
100 ng of LPS (from E. coli 055:B5; Sigma-Aldrich #L4524) on
days 0, 1, and 2 [17]. On day 14, mice were lightly anesthetized
with isoflurane and challenged intranasally with 25 mg of OVA or
Alexa Fluor 647 (AF)-OVA (Invitrogen) in 30 ml of PBS. As
determined with the limulus amebocyte assay (Cambrex), a total
dose of ,1.5 ng of contaminating LPS per mouse was delivered by
the OVA solutions during sensitizations and challenges. Mice were
euthanized before analyses at the times indicated in the Results
section.
Lung mononuclear cell isolation
Lungs were perfused with 10 ml of ice-cold calcium- and
magnesium-free Hanks’ Balanced Salt Solution through the right
ventricle, removed intact, and physically dissociated with a
gentleMACS Dissociator (Miltenyi Biotec). Lung fragments were
incubated with 500 U/ml collagenase (CLS-IV, Worthington
Biochemical) and 0.02 mg/ml DNAse I (Sigma-Aldrich) at 37uC
for 20 minutes with agitation at 200 rpm. Residual tissue
fragments were allowed to settle for 5 min, and the cell suspension
was removed and washed with 1 mM EDTA on ice. The residual
tissue fragments were digested again with fresh collagenase/
DNAse and processed the same way as the first digest. Cells were
pelleted by centrifugation, resuspended in RPMI medium, and the
two digests were pooled. Mononuclear cells were isolated from the
interface of a Nycoprep 1.077 (Axis-Shield) gradient (3006g for
20 minutes at 4uC). Cells were washed with PBS, counted, and
analyzed by flow cytometry.
Flow cytometry
Cells were resuspended in PBS containing 0.5% fetal bovine
serum (FBS) or bovine serum albumin (BSA) and 0.05% sodium
azide at 4uC and incubated with anti-FccRII/III monoclonal
antibody (mAb) (BD Biosciences) and mouse IgG (Sigma) for
20 minutes on ice to block FccR. Cells were then incubated with
saturating concentrations of fluorochrome conjugated anti-CD4,
CD11c (Biolegend), or LILRB4 [13] for 30 minutes at 4uC and
washed by centrifugation as previously described [16]. For
detection of CCR7, cells were incubated with mouse CCL19-
human Fc (eBioscience) for 30 minutes at 4uC. Cells were washed
by centrifugation, incubated with fluorochrome conjugated anti-
human IgG for 20 minutes at 4uC, and washed again. For
intracellular cytokine staining, cells were resuspended in media
containing 50 ng/ml phorbol myristate acetate (Sigma) and 1 mM
ionomycin (Calbiochem) and incubated for 2 hours at 37uC.
Monensin (2.5 mM; Sigma) was then added, and the cells were
incubated for 4 hours at 37uC, after which DNase I (50 mg/ml;
Sigma-Aldrich) was added, and the cells were incubated for
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(eBioscience), incubated for 20 minutes in the dark at room
temperature, washed twice by centrifugation with PBS containing
0.5% FBS or BSA and 0.05% sodium azide at 4uC, and washed
once in permeabilization buffer (eBioscience) by centrifugation.
Cells were resuspended in permeabilization buffer and incubated
with anti-FccRII/III mAb (BD Biosciences) and mouse IgG
(Sigma-Aldrich) as described above. Cells were then incubated
with saturating concentrations of fluorochrome conjugated anti-
CD4 and anti-IL-4 or anti-IL-5 (Biolegend) in permeabilization/
blocking buffer for 15 minutes in the dark on ice, and washed by
centrifugation with permeabilization buffer. Cells were then
incubated on ice in fresh permeabilization buffer for 10 minutes,
centrifuged, and resuspended in PBS containing 0.5% FBS or BSA
and 0.05% sodium azide. Data were acquired on a Becton
Dickinson FACSCanto flow cytometer using FACSDiva acquisi-
tion software, and data were analyzed with FlowJo software
(Treestar). Fluorescence compensation was set for each color such
that there was no cross-talk between detection channels.
Fluorescence immunohistology
Mice were euthanized by i.p. injection of pentobarbital and
exsanguinated by cardiac puncture. Lungs were perfused with
10 ml of ice-cold calcium- and magnesium-free Hanks’ Balanced
Salt Solution through the right ventricle. A 22-gauge plastic
cannula was inserted into the upper third of the trachea, and
0.4 ml of 4% paraformaldehyde was infused into the lungs. Lungs
were removed intact, at the hila, placed in 4% paraformaldehyde,
stored at 4uC, and embedded in paraffin blocks. Tissue sections
were deparaffinized, rehydrated, and underwent Ag retrieval by
incubation in Target Retrieval Solution (Dako; Cat. S1699) at
97uC for 30 minutes. Sections were then incubated in a mixture of
goat anti-mouse CCL21 (R&D Systems) and rabbit anti-mouse
lymphatic vessel endothelial receptor 1 (LYVE-1) (Cell Sciences) at
37uC for 1 h. The sections were washed and incubated in a
mixture of Alexa Fluor 488-labeled donkey anti-goat IgG (1:1000;
Invitrogen), Alexa Fluor 594-labeled chicken anti-rabbit IgG
(1:1000; Invitrogen), and nuclear dye (Hoechst 33342, Invitrogen)
at 37uC for 1 h. Sections were washed thoroughly with PBS and
mounted with Fluoro-Gel (Electron Microscopy Sciences). Lung
sections were viewed with an Eclipse 80i microscope (Nikon
Instruments, Inc.), and photomicrographs were acquired with the
Hamamatsu C10800 digital camera and HC Image software
1.1.3.1 (Hamamatsu Corp.).
Statistical analyses. Statistical significance was determined
using Student’s unpaired, two-tailed t-test or the Mann-Whitney
test. P values,0.05 were considered to be significant.
Results
Expression of LILRB4 on lung DCs
We previously reported that expression of LILRB4 is upregu-
lated on LN DCs 18 hours after a single inhalation of 100 ug of
OVA and 100 ng of LPS compared with inhalation of PBS in
Lilrb4
+/+ mice [16]. The increase occurred selectively in OVA
+
DCs rather than in OVA
2 DCs. To determine whether that
difference reflects the situation in the lung, Lilrb4
+/+ mice were
given PBS alone or containing 100 mg OVA and 100 ng LPS or
AF-labeled OVA and 100 ng LPS intranasally. After 15 h, mice
were euthanized, their lungs were removed, and total cells were
dispersed from the tissue by mechanical and enzymatic treatments.
Mononuclear cells were then isolated by density gradient
centrifugation. Any residual erythrocytes, dead cells, and debris
in the mononuclear cell population were excluded in flow
cytometric analysis by light scatter properties (Fig. 1A), and
CD11c
+/autofluorescence
2 cells (Fig. 1B) were analyzed for
LILRB4 expression. In mice treated with PBS, LILRB4 was
expressed on 55% of DCs with a mean fluorescence intensity
(MFI) of 273, whereas in mice given OVA and LPS, 84% of DCs
were LILRB4
+ with an MFI of 1012 (Figs. 1C and 1D). Cells from
mice treated with AF-OVA and LPS were further gated into AF-
OVA
2 and AF-OVA
+ populations, as defined by comparison with
cells from mice that received unlabeled OVA/LPS (Figs. 1E and
1F), and expression of LILRB4 was determined for each
population from mice that received AF-OVA (Figs. 1G and 1H).
Whereas 3860.6% of AF-OVA
2 DCs were LILRB4
+ with an
MFI of 14462.1 6 a significantly greater 9161.2% of AF-OVA
+
DCs were LILRB4
+ (P,0.0001, n=3) with a significantly greater
MFI of 1267653 (P,0.0001, n=3). Thus, uptake of Ag by lung
DCs in response to OVA and LPS is associated with increased
expression of LILRB4, which is maintained on DCs in the lung-
draining LNs [16].
Effects of LILRB4 deficiency on CCL21 expression in the
lung
We also previously reported that there are more OVA
+, mature
DCs in the lung-draining LNs of OVA/LPS-sensitized Lilrb4
2/2
mice compared with Lilrb4
+/+ mice 18 hours after a single
challenge with OVA [16]. To seek a mechanism by which the
absence of LILRB4 increases the migration of Ag-bearing DCs
from the lungs to the LNs, we considered that CCL21 expressed
by cells in the endothelium of lymphatic vessels makes a major
contribution to the migration of DCs from tissue sites to local
draining LNs [21,25,26,28,29]. In addition, CCL21 in the lung is
located in perivascular lymphatic vessels [22,23], and Ag-
challenged Lilrb4
2/2 mice have more perivascular lung inflam-
mation than Lilrb4
2/2 mice [16]. To determine whether CCL21
expression differed in the lungs of Lilrb4
+/+ and Lilrb4
2/2 mice
after Ag challenge, mice were sensitized with OVA and LPS or
sham sensitized with PBS as described above on days 0, 1, and 2;
mice were challenged with 25 mg of unlabeled OVA on day 14.
Four hours later, mice were euthanized, lungs were removed, and
tissue sections were prepared. As determined by two-color
fluorescence immunohistology with anti-LYVE-1 to detect lym-
phatic vessels [26,37,38] and anti-CCL21, immunoreactive
CCL21
+ cells were not detected in LYVE-1
+ lymphatics of mice
that were sham sensitized with PBS and then received OVA
(representative photomicrographs and quantification are presented
in Figs. 2A and 2B, respectively). In contrast, CCL21
+ cells were
detected in the lymphatic vessels of both Lilrb4
+/+ and Lilrb4
2/2
mice that had been sensitized with OVA/LPS and challenged with
OVA. However, there were more CCL21
+ cells in the lymphatics
of Lilrb4
2/2 mice compared with Lilrb4
+/+ mice. In contrast, there
were no differences in the number of LYVE-1
+ lung lymphatic
vessels in Lilrb4
+/+ and Lilrb4
2/2 mice as assessed immunohisto-
logically, and there were no differences in the levels of lung mRNA
encoding LYVE-1, vascular endothelial growth factor C, vascular
endothelial growth factor receptor 3, or podoplanin (data not
shown), which are molecules that can reflect or influence the
production of lymphatic vessels [37,39,40]. Hence, the data
indicate that the main effect of the absence of LILRB4 is greater
expression of CCL21 per lung lymphatic vessel.
Effects of LILRB4 deficiency on CCR7 expression on lung
DCs
The effects of CCL21 on DC chemotaxis towards, and
migration thorough, lymphatics are mediated by CCR7
Downregulation of DC Migration by LILRB4
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In addition, upregulation of CCR7 expression on DCs accompa-
nies maturation induced by LPS, TNF-a, and other proinflam-
matory mediators [33–36]. We therefore determined whether
expression of CCR7 is greater on Ag-bearing DCs from the lungs
of Lilrb4
2/2 mice at the same time that there is greater lymphatic
expression of CCL21, i.e., 4 hours after Ag challenge. Lilrb4
+/+
and Lilrb4
2/2 mice were sensitized with OVA/LPS as described
above and were challenged with AF-OVA on day 14 [16]. Four
hours later, lungs cells were mechanically and enzymatically
dispersed and mononuclear cells were isolated by density gradient
centrifugation. As assessed by flow cytometry, the percentage of
AF-OVA
+ DCs expressing CCR7 was significantly greater than
that of AF-OVA
2 DCs in both Lilrb4
+/+ and Lilrb4
2/2 mice
Figure 1. Expression of LILRB4 on lung DCs of Lilrb4
+/+ mice. Animals received PBS alone or containing 100 mg OVA and 100 ng LPS or 100 mg
AF-OVA and 100 ng LPS intranasally. After 15 h, mice were euthanized, lungs were enzymatically digested, and mononuclear cells were obtained by
density gradient centrifugation. Residual erythrocytes, dead cells, and debris were excluded in flow cytometric analysis by light scatter properties (A),
and CD11c
+/autofluorescence
2 cells (B) were analyzed for LILRB4 expression (C and D; shaded and open histograms are isotype control and anti-
LILRB4 staining, respectively). Fluorescence compensation was set for each color such that there was no cross-talk between detection channels. Cells
from mice treated with AF-OVA and LPS were further gated into AF-OVA
2 and AF-OVA
+ populations, as defined by cells from mice that received
unlabeled OVA/LPS (E and F), and expression of LILRB4 was determined for each population (G and H). CD11c
+/autofluorescence
+ cells (* in B) were
100% AF-OVA
+, and LILRB4 expression was significantly greater in mice that received AF-OVA compared with PBS (compiled data are reported in the
Results section).
doi:10.1371/journal.pone.0057007.g001
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+ DCs expressing
CCR7 was significantly greater in Lilrb4
2/2 mice compared with
Lilrb4
+/+ mice, whereas there was no difference in the percentage
of AF-OVA
2 DCs expressing CCR7 in the two strains of mice.
Similarly, the expression level of CCR7 as assessed by MFI was
significantly greater in AF-OVA
+ cells than in AF-OVA
2 DCs in
both strains of mice (Fig. 3B). In addition, there was a trend
(P=0.06) towards greater expression of CCR7 on AF-OVA
+ DCs
but not AF-OVA
2 DCs from Lilrb4
2/2 mice compared with
Lilrb4
+/+ mice. Hence, ingestion of inhaled Ag by lung DCs
resulted in upregulation of the CCL21 ligand CCR7 in both
strains, but the increases were greater in Lilrb4
2/2 mice and were
restricted to Ag
+ DCs. The selectivity of the phenotype for AF-
OVA
+ cells is in accordance with our finding that OVA
+ lung DCs
express significantly more LILRB4 than OVA
2 DCs in Lilrb4
+/+
mice (Fig. 1).
Effects of LILRB4 deficiency on Th2 cells in the lung
We previously found that in addition to the greater number of
Ag-bearing DCs in the LNs of Lilrb4
2/2 mice, there were also
more IL-4-producing and IL-5-producing lymphocytes 18 hours
after challenge, compared with Lilrb4
+/+ mice ([16] and unpub-
lished data). To determine whether the Th2 phenotype in the LNs
was accompanied by greater numbers of IL-4- and IL-5-producing
cells in the lungs of Lilrb4
2/2 mice, we compared by flow
cytometry the expression of those cytokines in CD4
+ cells in the
lungs of sensitized Lilrb4
+/+ and Lilrb4
2/2 mice 18 hours after
challenge. Both the percentage (Fig. 4A and B) and number of
CD4
+IL-4
+ cells were significantly greater in the lungs of Lilrb4
2/2
Figure 2. Expression of CCL21 in the lung lymphatics of Lilrb4
+/+ and Lilrb4
2/2 mice. Animals were sensitized with OVA and LPS (A; left and
middle panels) or sham sensitized with PBS (A; right panel) as described in the Fig. 1 legend on days 0, 1, and 2. Mice were challenged with 25 mgo f
unlabeled OVA intranasally on day 14. After 4 h, mice were euthanized, and paraffin-embedded sections of lungs were prepared. Tissue sections were
incubated with rabbit anti-mouse LYVE-1 and goat IgG anti-mouse CCL21. Tissue sections were washed and incubated with Alexa Fluor 488-labeled
donkey anti-goat IgG (green), Alexa Fluor 594-labeled chicken anti-rabbit IgG (red), and nuclear dye Hoechst 33342 (blue). Sections were washed,
mounted, and examined by fluorescence microscopy. Representative photomicrographs (A) and compiled data (B) are presented. Data in B are
expressed as mean 6 SEM; n=9–10.
doi:10.1371/journal.pone.0057007.g002
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percentage (Fig. 4A and C) and number of CD4
+IL-5
+ cells were
approximately half that of IL-4
+ cells, they were nevertheless
significantly greater in Lilrb4
2/2 mice, as was the MFI of IL-5
staining (Fig. 4B and 4C). These increases in the lungs of
challenged Lilrb4
2/2 mice are consistent with the exacerbated
Th2 pulmonary pathology they exhibit [16].
Discussion
We have established that the absence of LILRB4 leads to
changes in lung lymphatic endothelium and DCs that are
compatible with the increased migration of Ag-bearing DCs to
LNs and attendant increases in Th2 cells in LNs and lungs upon
challenge of Ag-sensitized Lilrb4
2/2 mice. Specifically, our
findings of greater expression of CCL21 on lung lymphatics and
CCR7 on lung DCs of Lilrb4
2/2 mice 4 hours after Ag challenge
provides a mechanism by which there are more Ag-bearing DCs
and Th2 cells in the LNs of Lilrb4
2/2 mice 18 hours after
challenge. More broadly, the results reported here establish that an
ITIM-bearing receptor can exert inhibitory effects by downreg-
ulating the expression of both a stromal chemokine and its cognate
receptor on immune system cells, leading to attenuated cell
migration and resulting pathologic allergic inflammation.
We previously reported that LILRB4 was expressed weakly on a
minority of DCs in the lung-draining LNs of Lilrb4
2/2 mice
18 hours after intranasal instillation of PBS [16]. Inhalation of AF-
OVA and LPS resulted in ,2- and 4-fold increases in the
percentage and number of LILRB4
+ LN DCs, respectively,
compared with mice that received PBS, but notably the increases
were entirely accounted for by OVA
+ DCs. However, it had not
been determined whether the increased expression of LILRB4
occurred before or after DCs arrived in the LNs. We now report
that the selective upregulation of LILRB4 on Ag-bearing DCs
Figure 3. Expression of CCR7 on lung DCs in Lilrb4
+/+ and Lilrb4
2/2 mice. Mice were sensitized with OVA/LPS and challenged with AF-OVA as
described in the legend for Fig. 1. After 4 h, lung mononuclear cells were obtained as described in the legend for Fig. 1, and
CD11c
+/autofluorescence
2 cells were analyzed by flow cytometry for the percentage (A) and MFI (B) of CCR7 expression on AF-OVA
+ and AF-
OVA
2 DCs. Fluorescence compensation was set for each color such that there was no cross-talk between detection channels. Data are expressed as
mean 6 SEM, n=5.
doi:10.1371/journal.pone.0057007.g003
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intranasally (Fig. 1). These findings are consistent with a lung
origin for Ag-bearing LN DCs in response to inhaled OVA and
LPS, and demonstrate the retention of upregulated expression of
LILRB4 as Ag-bearing DCs migrate from the lungs to the LNs.
The finding that upregulation of LILRB4 on DCs occurs
proximally in the tissue of origin on the cells destined to attract
Ag-specific T cells in the LNs indicates that LILRB4 expression
Figure 4. Expression of IL-4 and IL-5 by lung CD4
+ cells in Lilrb4
+/+ and Lilrb4
2/2 mice. Mice were sensitized and challenged with OVA as
described in the legend for Fig. 2. After 18 h, lung mononuclear cells were obtained as described in the legend for Fig. 1, and cells were analyzed by
intracellular flow cytometry to determine the percentage, number, and MFI of IL-4 and IL-5 in CD4
+ cells. Data from representative experiments show
dot plots for IL-4 and IL-5 (A); positivity was defined as cells that had fluorescence intensities greater than that of 99% of the same population of cells
when stained with an equal amount of isotype control mAbs. Compiled data for IL-4 (B) and IL-5 (C) are expressed as mean 6 SEM, n=8.
doi:10.1371/journal.pone.0057007.g004
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induced on the DCs that will shape immune and inflammatory
responses.
CD11c
+/autofluorescence
+ cells, characteristic of alveolar
macrophages (the population is marked with an asterisk in
Fig. 1B), were largely LILRB4
+ irrespective of whether mice had
been treated with PBS or with OVA and LPS (94% and 96%,
respectively), in contrast with DCs that exhibited an increase in the
percentage of LILRB4
+ cells from 55% to 84%. Nevertheless, the
level of expression of LILRB4 on alveolar macrophages was
augmented in response to OVA-LPS compared with PBS (MFI
values of 9,303 and 3,924, respectively. In mice that received AF-
OVA and LPS, essentially all alveolar macrophages were AF-
OVA
+ with an LILRB4 MFI of 9,8956244 (n=3), a value similar
to that of alveolar macrophages from mice that received unlabeled
OVA and LPS. Hence, expression of LILRB4 is upregulated on
both Ag-bearing DCs and macrophages in the lungs of mice in
response to OVA and LPS. In addition, the finding of comparable
MFIs for LILRB4 expression on macrophages in response to
unlabeled OVA/LPS and AF-OVA/LPS indicates that the
increased MFIs for LILRB4 are not due to the fluorescence of
AF-OVA being reported as expression of LILRB4.
We previously reported that LPS increases the expression of
LILRB4 on neutrophils in vivo [13]. We have also found that LPS
increases the MFI of LILRB4 on bone marrow-derived dendritic
cells (BMDCs) in vitro by approximately 2-fold, a magnitude similar
to that for BMDCs cultured in OVA and LPS (data not shown),
suggesting that LPS plays a key role in stimulating increased
expression of LILRB4 on mouse DCs.
In Lilrb4
2/2 mice, the major DC phenotype in this model
occurs in response to Ag challenge, i.e., greater numbers of Ag-
bearing DCs in the lung-draining LNs 18 hours after Ag challenge
compared with Lilrb4
+/+ mice [16]. However, the mechanism by
which LILRB4 regulates the number of Ag-bearing in the LNs was
unknown. We found that expression of the key DC migration
chemokine CCL21 [21–27] is significantly greater in the lung
lymphatic vessels [22,23] of these mice 4 hours after challenge
compared with their Lilrb4
+/+ counterparts (Fig. 2). Little
expression of immunoreactive CCL21 was detected on lymphatic
vessels of non-sensitized mice exposed to OVA (Fig. 2). Notably,
the immunoreactive CCL21 in sensitized and challenged mice
presented in a ‘‘patchy’’ appearance, which has been observed by
others [22,23,26,27], and may represent the recently-appreciated
localization of CCL21 at basement membrane portals and ‘‘flap’’
structures on lymphatics where the chemokine fosters docking of
migrating DCs, their migration into the vessel lumen, and
subsequent movement through the vessels [27,41]. The involve-
ment of CCL21 in multiple steps of DC migration from tissue to
lymphatics to LNs emphasizes the key role of this chemokine, and
provides an explanation as to how increased expression of CCL21
in Lilrb4
2/2 mice can contribute to the increased number of Ag-
bearing DCs that appear in the LNs.
Expression of CCL21 on lymphatic endothelium is upregulated
by mediators associated with inflammation, such as TNF-a, IL-1a
[30] lymphotoxin-a1b2 [42,43], and Oncostatin M [28]. We
found no differences in the levels of TNF-a, IL-1a, and Oncostatin
M mRNA or protein in whole lung extracts and in isolated lung
mononuclear cells from sensitized Lilrb4
+/+ and Lilrb4
2/2 mice
4 hours after challenge, as well as no difference in lymphotoxin-b
as determined by immunohistology (data not shown), suggesting
that the levels of these mediators in the lung do not account for the
enhanced expression of CCL21 in the pulmonary lymphatics of
Lilrb4
2/2 mice. It has recently been reported that increased
drainage of interstitial fluid through lymphatic vessels increases
lymphatic expression of CCL21 [44,45]. We have previously
reported that the absence of LILRB4 leads to increased vascular
permeability and tissue edema in two models of allergic responses
in the skin [46,47], raising the possibility that a similar response in
the lung might account for the heightened level of lymphatic
CCL21 in Lilrb4
2/2 mice.
The contribution of upregulated CCL21 in Lilrb4
2/2 mice with
respect to DC migration that we report here is reinforced by the
findings that CCR7 expressed on tissue DCs can be an essential
component in the mobilization of these cells through lymphatics
[22,24,27,29–31], particularly as CCR7 is the sole known receptor
for CCL21. We found that expression of CCR7 is significantly
greater on OVA
+ lung DCs compared with OVA
2 DCs in
response to challenge in both Lilrb4
+/+ and Lilrb4
2/2 mice (Fig. 3),
demonstrating that OVA
+ DCs were primed for directed
migration towards, and entry into, CCL21
+ lymphatics. Moreover,
we found that expression of CCR7 was significantly upregulated in
sensitized and challenged Lilrb4
2/2 mice compared with Lilrb4
+/+
mice (Fig. 3), which together with the increased expression of
CCL21, would provide enhanced capacity for migration of Ag-
bearing DCs in the absence of LILRB4. Expression of CCR7 on
DCs is regulated by cytokines such as IL-33 [48] and transforming
growth factor-b1 [49], as well as by prostaglandin (PG) E2 [57;58],
but we found no differences in the levels of these cytokines or the
PGE2 biosynthetic enzymes cyclooxygenase-1, cyclooxygenase-2,
and membrane PGEsynthetase1 inthe lungsof sensitized Lilrb4
+/+
and Lilrb4
2/2 mice after challenge (data not shown). Because
expression of CCR7 on DCs is upregulated by LPS [33–36], our
findings in Lilrb4
2/2 mice may therefore represent a direct
manifestation of the loss this endogenous negative regulator of
LPS responses on DCs.
The ability of a member of the human LILRB family to
downregulate expression of a chemokine receptor has been
reported for T cells that express LILRB1, the only human LILRB
expressed on that cell type. Expression of CXCR3 on human
CD4
+ T cells is reduced by exposure to soluble HLA-G (sHLA-G)
in vitro in a manner partially dependent on LILRB1, which is one
of the receptors for HLA-G [50]. sHLA-G-mediated downregu-
lation of CXCR3 expression on human NK cells in vitro is also
regulated in part by LILRB1 [51]. Our findings indicate that
mouse LILRB4 not only downregulates the extent of chemokine
receptor expression on DCs, but also is a biologically relevant
ligand in vivo.
Our prior studies indicated that the absence of LILRB4
increases the number of IL-4-producing LN lymphocytes after
challenge of sensitized mice [16]. We also reported that the lungs
of Lilrb4
2/2 contained significantly more CD4
+ cells, but it was
unknown whether those additional cells provided Th2 cytokines.
Our new data reveal that in the absence of LILRB4, there are
significantly more IL-4-producing and IL-5-producing CD4
+ cells
in the Ag-challenged lungs of Lilrb4
2/2 mice (Fig. 4). Because T
cells do not express LILRB4 in this model [16], it seems
reasonable to conclude that a driving force for the augmentation
of cells expressing Th2-cytokines in the LNs and lungs of Lilrb4
2/2
mice are the Ag-bearing lung DCs that lack the upregulated
expression of LILRB4 found in Lilrb4
+/+ mice, and their increased
migration to LNs under the aegis of increased CCL21 and CCR7
expression. Knock-down of LILRB4 expression in human DCs
leads to greater production of the T cell chemoattractants
CXCL10 (IP-10) and CXCL11 (I-TAC) in response to LPS-
induced maturation, and supernatants from these DCs promote
greater in vitro chemotaxis of activated T cells than supernatants
from DCs that express normal levels of LILRB4 [52], suggesting
another mechanism by which LILRB4 on DCs may regulate the
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inhibiting cell chemotaxis. Overall, our findings establish that in
the context of a model of pulmonary allergic inflammation,
LILRB4 downregulates DC-T cell interactions by inhibiting the
chemotaxis/migration of DCs from lung to secondary lymphoid
tissue and mitigating the pathobiologic linkage of innate and
adaptive immune inflammation.
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